Suppliers and packagers for ADAPALENE AND BENZOYL PEROXIDE

ADAPALENE AND BENZOYL PEROXIDE

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Actavis Labs Ut Inc	ADAPALENE AND BENZOYL PEROXIDE	adapalene; benzoyl peroxide	GEL;TOPICAL	209641	ANDA	Teva Pharmaceuticals, Inc.	0480-3154-45	1 BOTTLE, PUMP in 1 CARTON (0480-3154-45) / 45 g in 1 BOTTLE, PUMP	2022-11-28
Alembic	ADAPALENE AND BENZOYL PEROXIDE	adapalene; benzoyl peroxide	GEL;TOPICAL	214185	ANDA	Alembic Pharmaceuticals Limited	46708-662-45	1 BOTTLE, PUMP in 1 CARTON (46708-662-45) / 45 g in 1 BOTTLE, PUMP	2025-05-21
Alembic	ADAPALENE AND BENZOYL PEROXIDE	adapalene; benzoyl peroxide	GEL;TOPICAL	214185	ANDA	Alembic Pharmaceuticals Inc.	62332-662-45	1 BOTTLE, PUMP in 1 CARTON (62332-662-45) / 45 g in 1 BOTTLE, PUMP	2022-08-10
Encube	ADAPALENE AND BENZOYL PEROXIDE	adapalene; benzoyl peroxide	GEL;TOPICAL	206164	ANDA	Encube Ethicals, Inc.	21922-052-50	1 BOTTLE, PUMP in 1 CARTON (21922-052-50) / 45 g in 1 BOTTLE, PUMP	2023-08-14
Encube	ADAPALENE AND BENZOYL PEROXIDE	adapalene; benzoyl peroxide	GEL;TOPICAL	206164	ANDA	Bryant Ranch Prepack	72162-2296-2	1 BOTTLE, PUMP in 1 CARTON (72162-2296-2) / 45 g in 1 BOTTLE, PUMP	2023-08-14
Glenmark Pharms Ltd	ADAPALENE AND BENZOYL PEROXIDE	adapalene; benzoyl peroxide	GEL;TOPICAL	208108	ANDA	Glenmark Pharmaceuticals Inc., USA	68462-301-47	1 BOTTLE, PUMP in 1 CARTON (68462-301-47) / 45 g in 1 BOTTLE, PUMP	2019-11-08

ADAPALENE AND BENZOYL PEROXIDE DRUG SUPPLY CHAIN ANALYSIS

Last updated: February 19, 2026

This report analyzes the supply chain for adapalene and benzoyl peroxide, key active pharmaceutical ingredients (APIs) used in topical acne treatments. The analysis focuses on major manufacturers, regulatory compliance, and market trends impacting global supply. Key players in API synthesis for these compounds exhibit varying levels of backward integration and geographical concentration, influencing production costs and supply chain resilience.

Who Are the Key API Manufacturers for Adapalene and Benzoyl Peroxide?

Global production of adapalene and benzoyl peroxide APIs is concentrated among a select group of chemical manufacturers, primarily located in Asia and Europe. These companies are critical nodes in the pharmaceutical supply chain, directly impacting the availability and cost of finished topical acne medications.

Adapalene API Manufacturers:

• AllessaChemie GmbH: A German chemical company specializing in fine chemicals and custom synthesis, AllessaChemie is a significant producer of adapalene. They operate advanced manufacturing facilities in Germany.
• BOC Sciences: This U.S.-based supplier offers a broad range of pharmaceutical intermediates and APIs, including adapalene. They source and distribute from various global manufacturing sites.
• Farmabios S.p.A.: An Italian API manufacturer with a focus on sterile APIs and complex molecules, Farmabios is a known supplier of adapalene. Their manufacturing site is in Italy.
• Synthonix, Inc.: A U.S.-based company specializing in building blocks and custom synthesis for drug discovery and development, Synthonix also produces adapalene for pharmaceutical clients.
• Yingkou Chemical Pharmaceutical Co., Ltd.: A Chinese pharmaceutical ingredient manufacturer, Yingkou Chemical is a high-volume producer of adapalene, serving both domestic and international markets. Their facilities are located in Liaoning province.

Benzoyl Peroxide API Manufacturers:

• Acme-Hardesty Co.: A U.S. distributor and manufacturer of specialty chemicals, Acme-Hardesty supplies benzoyl peroxide, often sourced from large-scale chemical producers.
• Active-Chemicals GmbH: This German company produces and distributes a range of chemicals, including benzoyl peroxide, for various industrial and pharmaceutical applications.
• DuPont: A global chemical company, DuPont is a major producer of benzoyl peroxide, particularly for polymer applications, but also supplies pharmaceutical-grade material. Their production is distributed across multiple global sites.
• Jiangsu Sanjili Chemical Co., Ltd.: A Chinese manufacturer of organic peroxides and other fine chemicals, Jiangsu Sanjili is a significant global supplier of benzoyl peroxide.
• Nantong Changpeng Chemical Co., Ltd.: Another Chinese chemical producer, Nantong Changpeng manufactures benzoyl peroxide, contributing to the substantial supply originating from China.

Comparison of Manufacturer Scale and Geography:

Ingredient	Key Manufacturers (Representative)	Primary Production Regions	Typical Production Scale	Backward Integration Level
Adapalene	AllessaChemie, Farmabios, Yingkou Chemical	Europe, Asia	Medium to High	Moderate
Benzoyl Peroxide	DuPont, Jiangsu Sanjili, Nantong Changpeng, Acme-Hardesty (distributor)	North America, Asia	High	High (for some major players)

Major Chinese manufacturers often operate at higher volumes due to larger-scale chemical synthesis infrastructure, impacting global pricing dynamics. European and U.S. suppliers may focus on niche markets, higher purity grades, or custom synthesis for specialized pharmaceutical needs.

What Regulatory Standards Must These Suppliers Meet?

Suppliers of adapalene and benzoyl peroxide APIs must adhere to stringent regulatory frameworks to ensure product quality, safety, and efficacy for pharmaceutical use. These standards are overseen by global regulatory bodies and require robust quality management systems.

Key Regulatory Requirements:

• Good Manufacturing Practices (GMP): Compliance with cGMP (current Good Manufacturing Practices) is mandatory. This involves documented procedures for manufacturing, quality control, packaging, and storage. Regulatory bodies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) enforce GMP standards through inspections.
• Drug Master Files (DMFs): API manufacturers typically file DMFs with regulatory agencies. These confidential documents detail the chemistry, manufacturing, and controls (CMC) of the API. Pharmaceutical companies that use the API reference these DMFs in their drug product applications.
  • FDA DMFs: Contain detailed information on API manufacturing, facilities, and quality controls.
  • European EDMFs (European Drug Master Files): Similar to U.S. DMFs, used for EMA submissions.
• ICH Guidelines: International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) guidelines provide harmonized standards for pharmaceutical development and registration. Relevant ICH guidelines include:
  • ICH Q7: Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients.
  • ICH Q11: Development and Manufacture of Drug Substances.
• Pharmacopoeial Standards: APIs must meet the purity and quality specifications outlined in recognized pharmacopoeias, such as:
  • United States Pharmacopeia (USP): Sets standards for identity, strength, quality, and purity of medicines.
  • European Pharmacopoeia (Ph. Eur.): Provides similar standards for the European market.
  • Japanese Pharmacopoeia (JP): Standards for the Japanese market.
• REACH Compliance (for European Union): Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH) regulations apply to chemical substances manufactured or imported into the EU, including APIs. This ensures safe handling and use of chemicals.
• Impurity Profiling and Control: Manufacturers must identify, quantify, and control impurities in the API. This includes process-related impurities, degradation products, and residual solvents, as mandated by ICH Q3A/B/C guidelines.

Regulatory Landscape Snapshot:

Regulatory Body	Primary Focus	Key Document/Process	Impact on API Suppliers
FDA (U.S.)	Drug safety, efficacy, and manufacturing quality	cGMP, DMFs, Inspections	Mandatory compliance
EMA (Europe)	Harmonized pharmaceutical standards and regulatory processes	cGMP, EDMFs, Inspections	Mandatory compliance
ICH	Harmonization of technical requirements for drug registration	ICH Q7, Q11, Q3 Series	Global standard setting
USP/Ph. Eur.	Public standards for drug quality, purity, and strength	Monographs	Product specification

API manufacturers undergo regular audits by regulatory agencies and pharmaceutical clients to ensure ongoing compliance. Failure to meet these standards can result in import alerts, product recalls, and significant financial penalties, disrupting the supply chain.

What Are the Key Challenges and Trends in the Adapalene and Benzoyl Peroxide Supply Chain?

The supply chain for adapalene and benzoyl peroxide faces several challenges, including geopolitical risks, raw material price volatility, and evolving regulatory demands. Emerging trends indicate a shift towards greater supply chain resilience and sustainability.

Supply Chain Challenges:

• Geopolitical Instability and Trade Policies: Concentration of API manufacturing in certain regions, particularly China, makes the supply chain vulnerable to trade disputes, export restrictions, or regional conflicts. Tariffs and changing trade policies can impact import costs and lead times.
• Raw Material Availability and Price Volatility: The synthesis of adapalene and benzoyl peroxide relies on specific petrochemical derivatives and intermediate chemicals. Fluctuations in the price and availability of these upstream materials, driven by global energy markets and supply disruptions, directly affect API production costs.
• Quality Control and Counterfeiting: Maintaining consistent high quality across large-volume production is challenging. The risk of counterfeit or substandard APIs entering the supply chain necessitates rigorous supplier qualification and testing protocols by finished product manufacturers.
• Environmental Regulations: Increasing global scrutiny on chemical manufacturing processes, particularly concerning waste disposal and emissions, can lead to stricter environmental regulations. Compliance may require significant investment in new technologies and processes for API producers.
• Logistics and Transportation Disruptions: Global shipping delays, port congestion, and increased freight costs, exacerbated by events like the COVID-19 pandemic, can impact the timely delivery of APIs.

Emerging Trends:

• Diversification of Sourcing: Pharmaceutical companies are increasingly looking to diversify their API sourcing beyond single geographic regions to mitigate geopolitical and logistical risks. This involves exploring manufacturing capabilities in India, Southeast Asia, and even reshoring some production to North America and Europe, though at higher cost.
• Increased Demand for High-Purity APIs: As research into dermatological treatments advances, there is a growing demand for APIs with exceptionally low impurity profiles. This pushes manufacturers to invest in advanced purification technologies and stricter analytical methods.
• Focus on Supply Chain Transparency and Traceability: Pharmaceutical companies are demanding greater transparency from their API suppliers regarding origin, manufacturing processes, and quality assurance. Technologies like blockchain are being explored to enhance traceability from raw material to finished product.
• Sustainability Initiatives: Growing pressure from regulators, investors, and consumers is driving API manufacturers to adopt more sustainable production methods. This includes reducing energy consumption, minimizing waste generation, and developing greener chemical synthesis routes.
• Consolidation in the API Manufacturing Sector: Mergers and acquisitions among API manufacturers can lead to changes in market dynamics, potentially reducing competition or creating larger, more integrated supply chains.

Impact on Pharmaceutical Companies:

These challenges and trends necessitate proactive supply chain management by pharmaceutical companies. This includes building stronger relationships with multiple, qualified API suppliers, conducting thorough risk assessments, and maintaining sufficient inventory buffers for critical APIs. The cost of medication is directly influenced by these supply chain dynamics.

How Does the Patent Landscape Affect Adapalene and Benzoyl Peroxide Formulations?

The patent landscape for adapalene and benzoyl peroxide primarily relates to novel formulations, combination therapies, and specific delivery systems, rather than the core API molecules themselves, which are largely off-patent.

Key Patenting Areas:

• Combination Therapies: Patents are frequently filed for novel combinations of adapalene with benzoyl peroxide, or with other active ingredients (e.g., antibiotics, retinoids, salicylic acid). These patents claim specific synergistic effects, improved efficacy, or reduced side effects achieved by combining ingredients in particular ratios or formulations.
  • Example: A patent might claim a fixed-dose combination gel containing a specific concentration of adapalene and benzoyl peroxide with enhanced stability or improved skin penetration.
• Novel Delivery Systems: Innovations in topical drug delivery systems are a significant area of patent activity. This includes:
  • Microsphere or Nanoparticle Encapsulation: Patents may cover formulations where adapalene or benzoyl peroxide is encapsulated to control release, improve stability, or reduce skin irritation.
  • Controlled-Release Formulations: Technologies that ensure a steady release of the API over a prolonged period.
  • Emulsion and Gel Formulations: Patents can claim specific compositions of emulsifiers, gelling agents, or stabilizers that enhance the physical properties, texture, or penetration of the topical product.
• Specific Pharmaceutical Compositions: Patents can cover unique excipient combinations, pH ranges, or manufacturing processes that result in a superior finished product. These might address issues such as ingredient compatibility, product stability, or patient compliance.
• Methods of Treatment: While less common for established APIs, patents may be granted for novel therapeutic uses or specific patient populations benefiting from adapalene and benzoyl peroxide, particularly when used in combination or with a novel delivery method.

Patent Expiry and Generics:

• Adapalene: The primary patents on adapalene itself have long expired, allowing for the development and marketing of generic adapalene products.
• Benzoyl Peroxide: Benzoyl peroxide is a well-established chemical with no fundamental patents on its molecule.

The expiration of formulation patents can lead to increased generic competition for branded combination products. However, companies holding newer patents on advanced delivery systems or unique combinations can extend their market exclusivity beyond the initial API patent expiry.

Impact on Market Entry:

• New Entrants (Generics): Generic manufacturers typically focus on developing bioequivalent formulations that do not infringe on existing formulation patents. This often involves developing simpler formulations or waiting for key formulation patents to expire.
• Branded Innovators: Pharmaceutical companies continue to innovate by developing new formulations, combinations, and delivery systems to secure new patent protection and maintain market differentiation and profitability. This drives the need for ongoing R&D investment.

The patent landscape therefore dictates the competitive environment, influencing pricing, market share, and the pace of innovation for topical acne treatments containing adapalene and benzoyl peroxide.

Key Takeaways

• Concentrated API Manufacturing: Adapalene and benzoyl peroxide API production is dominated by a limited number of manufacturers, primarily in Asia and Europe.
• Stringent Regulatory Compliance: API suppliers must meet rigorous global GMP standards, pharmacopoeial requirements, and file Drug Master Files (DMFs).
• Supply Chain Vulnerabilities: The supply chain is susceptible to geopolitical risks, raw material price volatility, and logistical disruptions.
• Innovation in Formulations: Patent activity is focused on novel combinations, advanced delivery systems, and specific compositions, rather than the core API molecules.
• Generic Competition: The expiration of basic API patents allows for generic versions, while formulation patents extend market exclusivity for branded products.

FAQs

1. What is the primary regulatory hurdle for a new API supplier of adapalene or benzoyl peroxide? New API suppliers must establish robust quality management systems to comply with cGMP, obtain necessary site registrations and inspections from regulatory bodies like the FDA and EMA, and prepare comprehensive Drug Master Files (DMFs) for client drug product applications.

2. How can pharmaceutical companies mitigate supply chain risks for these APIs? Companies can mitigate risks by qualifying multiple API suppliers across different geographic regions, maintaining strategic inventory levels, conducting regular supplier audits, and closely monitoring geopolitical and market developments impacting upstream raw materials and logistics.

3. Are there any alternative synthetic routes for adapalene or benzoyl peroxide that could impact current supply chains? While significant research exists on synthetic chemistry, the established manufacturing processes for adapalene and benzoyl peroxide are cost-effective and widely adopted. Major shifts to radically different, unproven synthetic routes are unlikely without significant cost or purity advantages, or stringent new environmental mandates.

4. What is the typical lifecycle of a patent related to a novel adapalene/benzoyl peroxide formulation? A typical patent for a novel formulation can last up to 20 years from the filing date. However, market exclusivity for the branded product might be further influenced by regulatory data exclusivity periods and the specific claims of the patent, which may cover a particular composition, delivery system, or method of use.

5. How do fluctuations in the cost of raw materials for benzoyl peroxide, such as benzene derivatives, affect the final cost of acne creams? Significant price increases in benzene derivatives or other key precursors can directly increase the manufacturing cost of benzoyl peroxide API. This cost is then passed down through the supply chain, potentially leading to higher API prices for pharmaceutical manufacturers, which can, in turn, influence the wholesale and retail prices of finished topical acne medications, especially for generic versions.

Citations

[1] U.S. Food & Drug Administration. (n.d.). Good Manufacturing Practice (GMP). Retrieved from [FDA Website] [2] European Medicines Agency. (n.d.). Good manufacturing practice. Retrieved from [EMA Website] [3] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (n.d.). ICH Guidelines. Retrieved from [ICH Website] [4] United States Pharmacopeial Convention. (n.d.). Pharmacopeial Forum. Retrieved from [USP Website] [5] European Directorate for the Quality of Medicines & HealthCare. (n.d.). European Pharmacopoeia. Retrieved from [EDQM Website] [6] European Chemicals Agency. (n.d.). REACH. Retrieved from [ECHA Website] [7] U.S. Patent and Trademark Office. (n.d.). Patents. Retrieved from [USPTO Website] [8] World Intellectual Property Organization. (n.d.). Patents. Retrieved from [WIPO Website]